Wave Life Sciences’ Wave-007 update triggered a sharp selloff after the company reported mixed early-stage obesity data in its Phase I INLIGHT trial. Investors focused on a less than 1% placebo-adjusted body-weight reduction at six months and a modest waist circumference change versus expectations informed by FDA guidance. The stock reaction underscores how narrow early weight-loss readouts can shift market expectations for RNA-based obesity programs.